Today: 20 May 2026
Browse Category

NYSE:UAL 1 September 2025 - 11 March 2026

Why American Airlines Stock Is Falling Again as Fuel Shock Tests AAL’s 2026 Outlook

Why American Airlines Stock Is Falling Again as Fuel Shock Tests AAL’s 2026 Outlook

American Airlines shares fell about 3% to $11.11 premarket Wednesday as investors sold airline stocks on rising fuel costs and volatile oil prices. American faces greater pressure than Delta or United, with lower 2025 profits and higher sensitivity to jet fuel prices. Brent crude hovered near $91 a barrel, and jet fuel surged to $150–$200. American increased its revolving commitments to $3.11 billion but ended 2025 with $36.5 billion in debt.
11 March 2026
······
Delta Air Lines Stock Falls as Fuel-Cost Surge Clouds 2026 Outlook

Delta Air Lines Stock Falls as Fuel-Cost Surge Clouds 2026 Outlook

Delta Air Lines shares fell about 1% to $59.98 Tuesday as jet-fuel costs surged following Middle East conflict disruptions. Delta said each 1-cent rise in jet fuel adds $40 million to annual expenses, with fuel making up 17% of 2025 operating costs. United and American Airlines stocks also dropped. Delta canceled some New York–Tel Aviv flights through March 23.
10 March 2026
·····
Audio Tech Weekend Bombshells: Headphone Surprises, Speaker Launches & Industry Shakeups (Aug 31–Sep 1, 2025)

Audio Tech Weekend Bombshells: Headphone Surprises, Speaker Launches & Industry Shakeups (Aug 31–Sep 1, 2025)

Denon launched a subscription-only model for its new wireless earbuds, deactivating devices if payments lapse, sparking industry debate. United Airlines will equip premium cabins with Meridian noise-cancelling headphones starting September 1. Freedman Group and Audinate announced a partnership to integrate Dante networking into RØDE and Mackie products. AVIXA forecasts global pro AV revenue will hit $402 billion by 2030.
1 September 2025
···

Stock Market Today

  • Tesla Q1 2026 Earnings Beat; Stock Faces Mixed Outlook for 2030
    May 20, 2026, 10:24 AM EDT. Tesla (TSLA) reported Q1 2026 earnings per share (EPS) of $0.41, exceeding the $0.36 consensus, with automotive gross margin rising to 21.1% from 16.2%. Operating income increased 135.8% year-on-year (YoY), and services plus Full Self-Driving (FSD) revenue jumped 42% to $3.75 billion, with 1.28 million active FSD subscriptions up 51%. Despite strong fundamentals, Tesla shares fell 8.83% year-to-date to $409.99 amid skepticism about AI monetization and scaling autonomy. Wall Street's average target is about $412, while a proprietary model estimates a base case price of $510 by 2030, with a bull case of $645. Achieving $650 requires significant price-to-earnings multiple expansion or sharp EPS growth from AI ventures, amid challenges like increased operating expenses and production constraints.

Latest articles

POET Technologies Jumps After $400M AI Photonics Raise, Dilution Questions Linger

POET Technologies Jumps After $400M AI Photonics Raise, Dilution Questions Linger

20 May 2026
POET Technologies shares rose 11% to $14.55 in early Nasdaq trading Wednesday after closing a US$400 million direct offering of 19 million shares and warrants. The rebound followed an 8% drop Tuesday on dilution concerns. The company reported Q1 revenue of $503,389 and a net loss of $12.3 million. A recent $50 million order from Lumilens could scale to $500 million over five years if production ramps up.
Nokia’s U.S. Broadband Order Arrives While AI-Driven Gains Test Supply Chain

Nokia’s U.S. Broadband Order Arrives While AI-Driven Gains Test Supply Chain

20 May 2026
Nokia shares rose 3.37% in Helsinki trading Wednesday after the FCC conditionally approved its Beacons and ONT devices, exempting them from U.S. Covered List restrictions. Nokia also transferred 975,289 treasury shares to equity plan participants. Dell’Oro Group forecasts the optical transport equipment market will grow 16% in 2026, driven by AI data centers.
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

20 May 2026
Biogen completed its acquisition of Apellis Pharmaceuticals, removing APLS shares from Nasdaq and paying investors $41 per share plus a contingent value right tied to Syfovre sales. Apellis shareholders tendered 82.4% of outstanding stock before the offer expired May 13. Biogen shares rose 0.9% to $192.34 Wednesday. The CVR could pay up to $4 if Syfovre meets future sales targets.
Go toTop